CO2023000038A2 - Fusiones heterodiméricas de relaxina y usos de las mismas - Google Patents
Fusiones heterodiméricas de relaxina y usos de las mismasInfo
- Publication number
- CO2023000038A2 CO2023000038A2 CONC2023/0000038A CO2023000038A CO2023000038A2 CO 2023000038 A2 CO2023000038 A2 CO 2023000038A2 CO 2023000038 A CO2023000038 A CO 2023000038A CO 2023000038 A2 CO2023000038 A2 CO 2023000038A2
- Authority
- CO
- Colombia
- Prior art keywords
- relaxin
- heterodimeric
- treatment
- fusions
- fusion polypeptides
- Prior art date
Links
- 230000004927 fusion Effects 0.000 title abstract 4
- 102000003743 Relaxin Human genes 0.000 title abstract 3
- 108090000103 Relaxin Proteins 0.000 title abstract 3
- 229920001184 polypeptide Polymers 0.000 abstract 4
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 4
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 4
- 208000024172 Cardiovascular disease Diseases 0.000 abstract 1
- 206010019280 Heart failures Diseases 0.000 abstract 1
- 101001091088 Homo sapiens Prorelaxin H2 Proteins 0.000 abstract 1
- 102100034949 Prorelaxin H2 Human genes 0.000 abstract 1
- -1 host cells Substances 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 102000039446 nucleic acids Human genes 0.000 abstract 1
- 108020004707 nucleic acids Proteins 0.000 abstract 1
- 150000007523 nucleic acids Chemical class 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 239000013598 vector Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/64—Relaxins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/2221—Relaxins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Cardiology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Gastroenterology & Hepatology (AREA)
- Endocrinology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Heart & Thoracic Surgery (AREA)
- Wood Science & Technology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Toxicology (AREA)
- Hospice & Palliative Care (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
RESUMEN La presente invención se refiere a polipéptidos de fusión heterodiméricos de Relaxina, en particular, a polipéptidos de fusión heterodiméricos de Relaxina 2 y a usos de los mismos. Por tanto, la invención proporciona polipéptidos de fusión de Relaxina, moléculas de ácido nucleico, vectores, células hospedadoras, composiciones farmacéuticas y kits que comprenden los mismos y usos de los mismos, incluyendo métodos de tratamiento. Los polipéptidos y las composiciones de la invención pueden ser útiles, en particular, en el tratamiento de enfermedades cardiovasculares, por ejemplo, para el tratamiento de la insuficiencia cardíaca.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202063040250P | 2020-06-17 | 2020-06-17 | |
PCT/EP2021/066309 WO2021255127A1 (en) | 2020-06-17 | 2021-06-16 | Heterodimeric relaxin fusions and uses thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
CO2023000038A2 true CO2023000038A2 (es) | 2023-01-16 |
Family
ID=76584509
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CONC2023/0000038A CO2023000038A2 (es) | 2020-06-17 | 2023-01-03 | Fusiones heterodiméricas de relaxina y usos de las mismas |
Country Status (17)
Country | Link |
---|---|
US (2) | US11795205B2 (es) |
EP (1) | EP4168434A1 (es) |
JP (1) | JP2023530335A (es) |
KR (1) | KR20230024994A (es) |
CN (1) | CN115916813A (es) |
AR (1) | AR125007A1 (es) |
AU (2) | AU2021290997C1 (es) |
BR (1) | BR112022025019A2 (es) |
CA (1) | CA3186143A1 (es) |
CL (1) | CL2022003578A1 (es) |
CO (1) | CO2023000038A2 (es) |
CR (1) | CR20230015A (es) |
EC (1) | ECSP23002960A (es) |
IL (1) | IL298786A (es) |
MX (1) | MX2022016340A (es) |
TW (1) | TW202214673A (es) |
WO (1) | WO2021255127A1 (es) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2024015634A2 (en) * | 2022-07-15 | 2024-01-18 | Nutcracker Therapeutics, Inc. | Mrna therapies including sirp-alpha |
WO2024121362A1 (en) | 2022-12-09 | 2024-06-13 | Astrazeneca Ab | Dosing regimens using heterodimeric relaxin fusions |
WO2024184206A1 (en) | 2023-03-03 | 2024-09-12 | Astrazeneca Ab | Pharmaceutical formulation comprising heterodimeric relaxin fusion proteins and uses thereof |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1355919B1 (en) | 2000-12-12 | 2010-11-24 | MedImmune, LLC | Molecules with extended half-lives, compositions and uses thereof |
US8389475B2 (en) * | 2009-08-10 | 2013-03-05 | The Board Of Trustees Of The Leland Stanford Junior University | Relaxin analogs |
AU2011325833C1 (en) * | 2010-11-05 | 2017-07-13 | Zymeworks Bc Inc. | Stable heterodimeric antibody design with mutations in the Fc domain |
KR20140054009A (ko) * | 2011-07-01 | 2014-05-08 | 바이엘 인텔렉쳐 프로퍼티 게엠베하 | 릴랙신 융합 폴리펩타이드 및 그의 용도 |
AR094147A1 (es) | 2012-12-27 | 2015-07-15 | Bayer Pharma Aktiengellschaft | Polipeptidos de fusion con actividad de relaxina y sus usos |
EP3107938B1 (en) * | 2014-05-28 | 2022-05-04 | Zymeworks Inc. | Modified antigen binding polypeptide constructs and uses thereof |
JP2020505029A (ja) * | 2017-01-25 | 2020-02-20 | メディミューン,エルエルシー | リラキシン融合ポリペプチドおよびその使用 |
-
2021
- 2021-06-16 IL IL298786A patent/IL298786A/en unknown
- 2021-06-16 CR CR20230015A patent/CR20230015A/es unknown
- 2021-06-16 WO PCT/EP2021/066309 patent/WO2021255127A1/en active Application Filing
- 2021-06-16 CA CA3186143A patent/CA3186143A1/en active Pending
- 2021-06-16 JP JP2022577390A patent/JP2023530335A/ja active Pending
- 2021-06-16 AU AU2021290997A patent/AU2021290997C1/en active Active
- 2021-06-16 US US17/348,825 patent/US11795205B2/en active Active
- 2021-06-16 KR KR1020237001632A patent/KR20230024994A/ko active Search and Examination
- 2021-06-16 MX MX2022016340A patent/MX2022016340A/es unknown
- 2021-06-16 CN CN202180042080.5A patent/CN115916813A/zh active Pending
- 2021-06-16 BR BR112022025019A patent/BR112022025019A2/pt unknown
- 2021-06-16 EP EP21734103.1A patent/EP4168434A1/en active Pending
- 2021-06-17 TW TW110122051A patent/TW202214673A/zh unknown
- 2021-06-17 AR ARP210101647A patent/AR125007A1/es unknown
-
2022
- 2022-12-15 CL CL2022003578A patent/CL2022003578A1/es unknown
-
2023
- 2023-01-03 CO CONC2023/0000038A patent/CO2023000038A2/es unknown
- 2023-01-16 EC ECSENADI20232960A patent/ECSP23002960A/es unknown
- 2023-07-01 US US18/346,205 patent/US20240025958A1/en active Pending
-
2024
- 2024-01-05 AU AU2024200074A patent/AU2024200074A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
KR20230024994A (ko) | 2023-02-21 |
BR112022025019A2 (pt) | 2022-12-27 |
US20220017591A1 (en) | 2022-01-20 |
MX2022016340A (es) | 2023-01-24 |
TW202214673A (zh) | 2022-04-16 |
CL2022003578A1 (es) | 2023-06-09 |
AU2021290997C1 (en) | 2024-01-04 |
ECSP23002960A (es) | 2023-03-31 |
JP2023530335A (ja) | 2023-07-14 |
CN115916813A (zh) | 2023-04-04 |
IL298786A (en) | 2023-02-01 |
AU2021290997B2 (en) | 2023-10-12 |
US11795205B2 (en) | 2023-10-24 |
WO2021255127A1 (en) | 2021-12-23 |
AR125007A1 (es) | 2023-05-31 |
CA3186143A1 (en) | 2021-12-23 |
AU2021290997A1 (en) | 2023-02-09 |
AU2024200074A1 (en) | 2024-01-25 |
CR20230015A (es) | 2023-02-17 |
US20240025958A1 (en) | 2024-01-25 |
EP4168434A1 (en) | 2023-04-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CO2023000038A2 (es) | Fusiones heterodiméricas de relaxina y usos de las mismas | |
BR112021005769A2 (pt) | proteínas de ligação a dll3 e métodos de uso | |
ECSP088262A (es) | Proteínas de fusión de albúmina | |
BR112022016550A2 (pt) | Proteínas de ligação a flt3 e métodos de uso | |
CY1117401T1 (el) | Πρωτεϊνες συντηξης αλβουμινης | |
AR076541A1 (es) | Mutantes de fgf21 y usos del mismo | |
BR112012006501A8 (pt) | Polipeptídios e usos dos mesmos | |
BR112022027096A2 (pt) | Composições e métodos relacionados a agentes terapêuticos ativáveis | |
BR112022013236A2 (pt) | Anticorpos anti-cd73 e usos dos mesmos | |
BR112012029588A2 (pt) | materiais biológicas relacionados a her3. | |
Cherdkiatikul et al. | Production of the α and β subunits of Spirulina allophycocyanin and C-phycocyanin in Escherichia coli: A comparative study of their antioxidant activities | |
AR013528A1 (es) | PROTEíNA-2 QUIMIOTÁCTICA MONOCíTICA (MCP-2) HUMANA AMINO TERMINALMENTE TRUNCADA, MOLÉCULA DE ADN QUE LA CODIFICA, VECTOR DE EXPRESIoN Y CÉLULA HUÉSPED CORRESPONDIENTES, PROCESO RECOMBINANTE PARA PREPARAR DICHAS PROTEíNAS, USO DE DICHAS PROTEíNAS PARA LA FABRICACIoN DE UN MEDICAMENTO uTIL PARA LA TER | |
CO2020000369A2 (es) | Polipéptidos que se unen al componente del complemento c5 o albumina sérica y proteínas de fusión de los mismos | |
Palasuberniam et al. | Snake venom proteomics of samar cobra (Naja samarensis) from the southern Philippines: Short alpha-neurotoxins as the dominant lethal component weakly cross-neutralized by the philippine cobra antivenom | |
Wintrode et al. | Solution structure and dynamics of a heat shock protein assembly probed by hydrogen exchange and mass spectrometry | |
CO2023003453A2 (es) | Proteínas de fusión inmunogénicas de coronavirus y métodos relacionados | |
CO2024010639A2 (es) | Inserción de anti-tfr:gaa y anti-cd63:gaa para el tratamiento de la enfermedad de pompe | |
CR20170507A (es) | Fusiones de variante iii del receptor de factor de crecimiento epidérmico-mesotelina y métodos para usar los mismos. | |
O'Leary et al. | The physiologic basis of surgery | |
BR112022008201A2 (pt) | Degradação de proteínas de superfície usando agente de ligação biespecífico | |
BR112021019139A2 (pt) | Célula de mamífero manipulada, composição, molécula isolada de dna de fita dupla, dispositivo implantável, cápsula de hidrogel, e, método de tratamento de um paciente com doença de fabry | |
BR112021012601A2 (pt) | Polipeptídeos ativadores de plasminogênio do tipo uroquinase modificados e métodos de uso | |
BR112023025331A2 (pt) | Proteína multiespecífica, composição farmacêutica, célula recombinante, ácido nucleico ou conjunto de ácidos nucleicos, uso de uma proteína ou composição, métodos ou uso | |
ECSP22056585A (es) | Variantes de alfa-glucosidasa ácida diseñadas por ingeniería | |
BR112017021016A2 (pt) | preparação de proteína, composição farmacêutica, proteína de fusão, polinucleotídeo isolado, estrutura de ácido nucleico, método para tratamento de doença ou condição associada ao excesso de glutamato, e método de purificação de um polipeptídeo |